- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions

European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
Pharmaceuticals - Community Register
Community register of medicinal products for human use |
AUTHORISED |
Product information |
| Invented name: | Zavesca
|
| Auth. number : | EU/1/02/238 |
| Active substance : | Miglustat |
| Orphan market exclusivity for "Treatment of Gaucher Disease" (based on designation EU/3/00/006) started on 21/11/2002 10 years of market exclusivity This orphan market exclusivity has ended on 21/11/2012 Orphan market exclusivity for "Treatment of Niemann-Pick disease, type C" (based on designation EU/3/06/351) started on 28/01/2009 10 years of market exclusivity This orphan market exclusivity will expire on 28/01/2019 | |
| ATC: | Anatomical main group: A - Alimentary tract and metabolism Therapeutic subgroup: A16 - Other alimentary tract and metabolism products Pharmacological subgroup: A16A - Other alimentary tract and metabolism products Chemical subgroup: A16AX - Various alimentary tract and metabolism products Chemical substance: A16AX06 - Miglustat (See WHO ATC Index) |
| Indication: | Zavesca is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable. Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease. |
| Marketing Authorisation Holder: | Actelion Registration Ltd
Chiswick Tower, 13th floor, 389 Chiswick High Road, London W4 4AL, United Kingdom |
|
EPAR and active package presentations | |
Package presentations | |
|
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information". Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register. |
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 21/11/2002 | Centralised - Authorisation | EMEA/H/C/435 | (2002)4579 of 20/11/2002 | |||
| 05/02/2003 | Centralised - Transfer Marketing Authorisation Holder | EMEA/H/C/435/T/1 | (2003)480 of 03/02/2003 | |||
| 22/04/2003 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/435/I/2 | ||||
| 10/10/2003 | Centralised - Variation | EMEA/H/C/435/I/3 | (2003)3724 of 08/10/2003 | |||
| 23/08/2004 | Centralised - Annual reassessment | EMEA/H/C/435/S/4 | (2004)3264 of 18/08/2004 | |||
| 15/10/2004 | Centralised - Variation | EMEA/H/C/435/IA/9 | ||||
| Updated with Decision(2005)1733 of 03/06/2005 | ||||||
| 15/10/2004 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/435/IA/5 | ||||
| 08/11/2004 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/435/IB/7 | ||||
| 08/12/2004 | Centralised - Variation | EMEA/H/C/435/IB/8 | ||||
| Updated with Decision(2005)1733 of 03/06/2005 | ||||||
| 08/12/2004 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/435/IB/6 | ||||
| 11/01/2005 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/435/IB/10 | ||||
| 07/06/2005 | Centralised - Annual reassessment | EMEA/H/C/435/II/S/11 | (2005)1733 of 03/06/2005 | |||
| 26/09/2005 | Centralised - Notification | EMEA/H/C/435/N/12 | ||||
| Updated with Decision(2006)1741 of 24/04/2006 | ||||||
| 16/11/2005 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/435/IA/14 | ||||
| 16/11/2005 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/435/IB/13 | ||||
| 26/04/2006 | Centralised - Annual reassessment | EMEA/H/C/435/S/15 | (2006)1741 of 24/04/2006 | |||
| 25/07/2006 | Centralised - Variation | EMEA/H/C/435/IA/17 | ||||
| Updated with Decision(2007)606 of 20/02/2007 | ||||||
| 25/07/2006 | Centralised - Variation | EMEA/H/C/435/IA/18 | ||||
| Updated with Decision(2007)606 of 20/02/2007 | ||||||
| 27/09/2006 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/435/II/16 | ||||
| 12/10/2006 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/435/IA/20 | ||||
| 22/02/2007 | Centralised - Variation | (2007)606 of 20/02/2007 | ||||
| 02/03/2007 | Centralised - Variation | EMEA/H/C/435/II/19 | (2007)748 of 28/02/2007 | |||
| 25/05/2007 | Centralised - Annual reassessment | EMEA/H/C/435/S/23 | (2007)2258 of 22/05/2007 | |||
| 11/09/2007 | Centralised - Renewal | EMEA/H/C/435/R/24 | (2007)4254 of 07/09/2007 | |||
| 19/12/2007 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/435/II/25 | ||||
| 20/03/2008 | Centralised - Variation | EMEA/H/C/435/II/26 | (2008)1176 of 18/03/2008 | |||
| 22/05/2008 | Centralised - Annual reassessment | EMEA/H/C/435/S/27 | (2008)2027 of 20/05/2008 | |||
| 30/10/2008 | Centralised - Variation | EMEA/H/C/435/II/28 | (2008)6487 of 28/10/2008 | |||
| 28/01/2009 | Centralised - Variation | EMEA/H/C/435/II/29 | (2009)555 of 26/01/2009 | |||
| 28/05/2009 | Centralised - Annual reassessment | EMEA/H/C/435/S/30 | (2009)4217 of 26/05/2009 | |||
| 17/12/2009 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/435/IB/31 | ||||
| 04/06/2010 | Centralised - Annual reassessment | EMEA/H/C/435/S/32 | (2010)3645 of 02/06/2010 | |||
| 18/05/2011 | Centralised - Annual reassessment | EMEA/H/C/435/S/33 | (2011)3534 of 16/05/2011 | |||
| 28/12/2011 | Centralised - Variation | EMEA/H/C/435/II/34 | (2011)10102 of 22/12/2011 | |||
| 27/08/2012 | Centralised - Annual reassessment | EMEA/H/C/435/S/36 | (2012)5997 of 23/08/2012 | |||
| 04/10/2012 | Centralised - Variation | EMEA/H/C/435/IA/38/G | ||||
| Updated with Decision(2013)5444 of 12/08/2013 | ||||||
| 10/10/2012 | Centralised - Renewal | EMEA/H/C/435/R/37 | (2012)7153 of 08/10/2012 | |||
| 21/11/2012 | Centralised - (orphan status) | |||||
| 01/02/2013 | Centralised - Variation | EMEA/H/C/435/IB/40/G | ||||
| Updated with Decision(2013)5444 of 12/08/2013 | ||||||
| 04/07/2013 | Centralised - Notification | EMEA/H/C/435/N/42 | ||||
| Updated with Decision(2014)8176 of 27/10/2014 | ||||||
| 14/08/2013 | PSUSA - Modification | EMEA/H/C/435/PSU/45 | (2013)5444 of 12/08/2013 | |||
| 12/11/2013 | Centralised - Variation | EMEA/H/C/435/IB/43 | ||||
| Updated with Decision(2014)8176 of 27/10/2014 | ||||||
| 07/04/2014 | Centralised - Notification | EMEA/H/C/435/N/45 | ||||
| Updated with Decision(2014)8176 of 27/10/2014 | ||||||
| 29/10/2014 | Centralised - Yearly update | (2014)8176 of 27/10/2014 | ||||
| 07/09/2015 | Centralised - Variation | EMEA/H/C/435/IG/612 | ||||
| Updated with Decision(2016)5268 of 08/08/2016 | ||||||
| 12/10/2015 | Centralised - Notification | EMEA/H/C/435/N/51 | ||||
| Updated with Decision(2016)5268 of 08/08/2016 | ||||||
| 10/08/2016 | Centralised - Yearly update | (2016)5268 of 08/08/2016 | ||||
| 16/08/2016 | Centralised - Variation | EMEA/H/C/435/IG/0720 | ||||
| Updated with Decision(2017)5256 of 19/07/2017 |


